Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 5 of 5 for “"interferon beta-1a"”.
-
Oral Pharmacotherapy for Relapsing-Remitting Multiple Sclerosis: Systematic Review and Indirect Treatment Comparison
… of oral therapies compared to placebo and interferon beta-1a in adults with relapsing-remitting multiple sclerosis (RRMS).</p> <p><strong><em> </em></strong></p> <p><strong><em>Search methods </em></strong></p> <p>We searched the MEDLINE, EMBASE, Cochrane Library, Web of Science (January …
-
Išsėtinė sklerozė ir kitos autoimuninės nervų sistemos ligos: klinikinis atvejis /
… challenges, as first-line immunomodulating drugs interferon beta – 1a, dimethyl fumarate was not effective, and a second line treatment with monoclonal antibody medications rituximab and ocrelizumab showed efficacy on both diseases, myasthenia gravis and multiple sclerosis. The presented case …
-
Patterns of Autoantibody Expression in Multiple Sclerosis and Systemic Lupus Erythematosus Unveiled Through the Development of an Autoantigen Discovery Technology
… clinical trial, which assessed the effects of interferon beta-1a (Rebif®) on the conversion from CIS to MS. Serum autoantibodies from MS patients significantly and reproducibly enriched for known and novel protein targets; 166 targets were selected by >10% of patients’ sera. Further, 10 …
-
Untersuchung der Sicherheit und Verträglichkeit von Interferon-beta-1b bei Kindern und Jugendlichen mit Multipler Sklerose
… in einer immunmodulatorischen Basistherapie mit Interferon-beta-1a (INFß-1a, i.m./ s.c.), Interferon-beta-1b (INFß-1b) oder Glatirameracetat. Für Beta-Interferone wurde hierbei die Sicherheit, Verträglichkeit und Effektivität, hier insbesondere die einer möglichst früh einsetzenden Behandlung, in …
-
Prescribing patterns of biologic immunomodulating medicine in the South African private health care sector
… item with adalimumab, etanercept, infliximab, interferon beta-1a, interferon 1-b or rituximab as active ingredient and who were diagnosed with either rheumatoid arthritis (RA), multiple sclerosis (MS) or Crohn's disease between 1 January 2005 and 31 December 2008. Between 2005 and 2008, an …